Published in Nature on March 09, 2015
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) | NCT04193696
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell (2015) 2.12
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov (2015) 1.67
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell (2016) 1.57
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Toward understanding and exploiting tumor heterogeneity. Nat Med (2015) 1.51
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature (2017) 1.46
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol (2017) 1.41
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity (2016) 1.21
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell (2016) 1.21
PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2015) 1.16
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch (2016) 1.10
Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature (2017) 1.09
Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer (2016) 1.08
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer (2016) 1.06
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol (2016) 1.05
Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet (2016) 1.05
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer (2015) 1.03
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res (2015) 0.99
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discov (2016) 0.97
Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res (2016) 0.96
TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest (2015) 0.96
Temporally-Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res (2017) 0.95
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol (2016) 0.94
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol (2016) 0.94
Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. Clin Cancer Res (2015) 0.92
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget (2016) 0.92
Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med (2015) 0.92
A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys (2016) 0.89
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer (2015) 0.88
Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun (2016) 0.87
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res (2016) 0.87
Immune checkpoint inhibitors: a new frontier in bladder cancer. World J Urol (2015) 0.87
T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy. Oncotarget (2016) 0.86
Genomic and Epigenomic Alterations in Cancer. Am J Pathol (2016) 0.86
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget (2016) 0.86
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci (2016) 0.85
Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS One (2016) 0.84
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer (2016) 0.84
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Radiotherapy and immune checkpoint blockade: potential interactions and future directions. Trends Mol Med (2015) 0.84
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy (2015) 0.84
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Front Immunol (2016) 0.84
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion. J Natl Cancer Inst (2017) 0.84
Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection. J Am Soc Nephrol (2016) 0.84
Interferons and the Immunogenic Effects of Cancer Therapy. Trends Immunol (2015) 0.84
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. Cell Rep (2016) 0.83
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 0.83
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) (2016) 0.82
Immunotherapy: A triple blow for cancer. Nat Rev Cancer (2015) 0.82
Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med (2016) 0.82
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol (2015) 0.82
Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. Int J Radiat Oncol Biol Phys (2016) 0.82
Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol (2016) 0.82
In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res (2016) 0.82
Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A (2015) 0.82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis (2016) 0.81
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med (2016) 0.81
Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther (2015) 0.81
Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer (2016) 0.81
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep (2016) 0.81
Meeting report: Metastasis Research Society-Chinese Tumor Metastasis Society joint conference on metastasis. Clin Exp Metastasis (2017) 0.80
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells? Front Immunol (2015) 0.80
Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80
Linc-POU3F3 promotes cell proliferation in gastric cancer via increasing T-reg distribution. Am J Transl Res (2015) 0.80
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology (2016) 0.79
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer (2015) 0.79
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov (2016) 0.79
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunol Immunother (2016) 0.79
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma (2016) 0.79
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol (2016) 0.79
Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res (2015) 0.79
Radiotherapy complements immune checkpoint blockade. Cancer Cell (2015) 0.79
Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology (2015) 0.79
T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol (2016) 0.78
Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res (2015) 0.78
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res (2015) 0.78
Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. Mediators Inflamm (2016) 0.78
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res (2016) 0.78
Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer (2017) 0.78
Immunomodulation: checkpoint blockade etc. Neuro Oncol (2015) 0.78
Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Mol Ther (2015) 0.78
Synthetic RORγt Agonists Enhance Protective Immunity. ACS Chem Biol (2016) 0.78
PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment. Front Immunol (2016) 0.78
Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology (2016) 0.78
Focus on Nivolumab in NSCLC. Front Med (Lausanne) (2016) 0.78
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
T cell exhaustion. Nat Immunol (2011) 11.08
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Analysis of microarray data using Z score transformation. J Mol Diagn (2003) 6.82
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell (2012) 5.77
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 4.14
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
Solving the protein sequence metric problem. Proc Natl Acad Sci U S A (2005) 2.78
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 2.50
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
Random forests for genomic data analysis. Genomics (2012) 1.98
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
Methods for diversity and overlap analysis in T-cell receptor populations. J Math Biol (2012) 1.30
Tracking global changes induced in the CD4 T-cell receptor repertoire by immunization with a complex antigen using short stretches of CDR3 protein sequence. Bioinformatics (2014) 1.17
Trophoblast CD274 (B7-H1) is differentially expressed across gestation: influence of oxygen concentration. Biol Reprod (2005) 1.14